Fig. 1.

Schedule of experimental approaches, pharmacological treatments, behavioral tests, and Western blotting analysis. In the first experimental approach, female Swiss mice were administered orally (p.o.) with vehicle or guanosine (0.05 mg/kg, p.o.), and 60 min after the treatments, they were subjected to the tail suspension test and open-field test (10 min apart). After the behavioral tests, mice were immediately euthanized by decapitation and the hippocampus and prefrontal cortex were dissected to measure the immunocontent of adenosine A₁R and A_2AR by Western blotting (A). In the second experimental approach, mice were pretreated with vehicle, caffeine (3 mg/kg, i.p.), DPCPX (2 mg/kg, i.p.), or ZM241385 (1 mg/kg, i.p.) and 30 min after the treatments, they received the administration of vehicle or guanosine (0.05 mg/kg, p.o.). Following 60 min of the treatments, mice were subjected to the tail suspension test and open-field test (B). In the third experimental approach, mice were treated with vehicle or guanosine (0.05 mg/kg, p.o.), and following 30 min, they received the administration of adenosine (0.5 mg/kg, i.p.), CHA (0.05 mg/kg, i.p.), or DPMA (0.1 mg/kg, i.p.). After 30 min of the treatments, mice were subjected to the tail suspension test and open-field test (C). Figure designed using images from Mind the Graph